Free Trial
NYSE:BDX

Becton, Dickinson and Company (BDX) Stock Price, News & Analysis

Becton, Dickinson and Company logo
$238.05 -2.32 (-0.97%)
As of 01/22/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Becton, Dickinson and Company Stock (NYSE:BDX)

Key Stats

Today's Range
$236.11
$239.96
50-Day Range
$220.02
$240.19
52-Week Range
$218.75
$248.42
Volume
1.35 million shs
Average Volume
2.08 million shs
Market Capitalization
$69.04 billion
P/E Ratio
40.08
Dividend Yield
1.75%
Price Target
$283.50
Consensus Rating
Buy

Company Overview

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Becton, Dickinson and Company Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
98th Percentile Overall Score

BDX MarketRank™: 

Becton, Dickinson and Company scored higher than 98% of companies evaluated by MarketBeat, and ranked 31st out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Becton, Dickinson and Company are expected to grow by 8.73% in the coming year, from $14.43 to $15.69 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Becton, Dickinson and Company is 40.08, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.59.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Becton, Dickinson and Company is 40.08, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.11.

  • Price to Earnings Growth Ratio

    Becton, Dickinson and Company has a PEG Ratio of 1.72. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Becton, Dickinson and Company has a P/B Ratio of 2.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Becton, Dickinson and Company's valuation and earnings.
  • Percentage of Shares Shorted

    1.29% of the float of Becton, Dickinson and Company has been sold short.
  • Short Interest Ratio / Days to Cover

    Becton, Dickinson and Company has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Becton, Dickinson and Company has recently increased by 41.83%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Becton, Dickinson and Company pays a meaningful dividend of 1.75%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Becton, Dickinson and Company has been increasing its dividend for 35 years.

  • Dividend Coverage

    The dividend payout ratio of Becton, Dickinson and Company is 70.03%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Becton, Dickinson and Company will have a dividend payout ratio of 26.51% next year. This indicates that Becton, Dickinson and Company will be able to sustain or increase its dividend.

  • Read more about Becton, Dickinson and Company's dividend.
  • Percentage of Shares Shorted

    1.29% of the float of Becton, Dickinson and Company has been sold short.
  • Short Interest Ratio / Days to Cover

    Becton, Dickinson and Company has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Becton, Dickinson and Company has recently increased by 41.83%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Becton, Dickinson and Company has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 36 news articles for Becton, Dickinson and Company this week, compared to 12 articles on an average week.
  • Search Interest

    24 people have searched for BDX on MarketBeat in the last 30 days. This is an increase of 9% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added Becton, Dickinson and Company to their MarketBeat watchlist in the last 30 days. This is an increase of 13% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Becton, Dickinson and Company insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,210,716.00 in company stock.

  • Percentage Held by Insiders

    Only 0.36% of the stock of Becton, Dickinson and Company is held by insiders.

  • Percentage Held by Institutions

    86.97% of the stock of Becton, Dickinson and Company is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Becton, Dickinson and Company's insider trading history.
Receive BDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Becton, Dickinson and Company and its competitors with MarketBeat's FREE daily newsletter.

BDX Stock News Headlines

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong
Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.
Becton Dickinson price target lowered to $278 from $312 at Barclays
Masimo names Becton Dickinson's Katie Szyman CEO
See More Headlines

BDX Stock Analysis - Frequently Asked Questions

Becton, Dickinson and Company's stock was trading at $226.87 at the beginning of 2025. Since then, BDX stock has increased by 4.9% and is now trading at $238.0460.
View the best growth stocks for 2025 here
.

Becton, Dickinson and Company (NYSE:BDX) announced its earnings results on Thursday, November, 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping analysts' consensus estimates of $3.77 by $0.04. The company's revenue was up 6.9% on a year-over-year basis.
Read the conference call transcript
.

Becton, Dickinson and Company subsidiaries include Cytognos, Scanwell Health Inc., Tissuemed Ltd., Venclose Inc., Tepha Inc., Velano Vascular, GSL Solutions, and more.

Becton, Dickinson and Company's top institutional shareholders include Nordea Investment Management AB (0.98%), Fort Washington Investment Advisors Inc. OH (0.27%), AMI Asset Management Corp (0.10%) and Avity Investment Management Inc. (0.05%). Insiders that own company stock include Thomas E Polen Jr, Claire Fraser, Shana Carol Neal, Roland Goette, Samrat S Khichi, David Shan, Michael David Garrison, David Hickey, Richard Byrd, Thomas J Spoerel, Alexandre Conroy and Betty D Larson.
View institutional ownership trends
.

Shares of BDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Becton, Dickinson and Company investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Exxon Mobil (XOM), Broadcom (AVGO), AbbVie (ABBV) and Chevron (CVX).

Company Calendar

Last Earnings
11/07/2024
Ex-Dividend for 12/31 Dividend
12/09/2024
Dividend Payable
12/31/2024
Today
1/22/2025
Next Earnings (Estimated)
2/06/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
07588710
Employees
74,000
Year Founded
1897

Price Target and Rating

Average Stock Price Target
$283.50
High Stock Price Target
$312.00
Low Stock Price Target
$270.00
Potential Upside/Downside
+19.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$1.71 billion
Pretax Margin
9.94%

Debt

Sales & Book Value

Annual Sales
$20.18 billion
Cash Flow
$21.20 per share
Book Value
$89.57 per share

Miscellaneous

Free Float
288,964,000
Market Cap
$69.04 billion
Optionable
Optionable
Beta
0.39

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

This page (NYSE:BDX) was last updated on 1/23/2025 by MarketBeat.com Staff
From Our Partners